Clinical trial
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or…
NCT00423397 · University of California, San Diego, Other · Unknown status
Key facts
| NCT number | NCT00423397 |
|---|---|
| Title | Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer |
| Official title | A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin |
| Lead sponsor | University of California, San Diego, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-melanomatous Skin Cancer |
| Intervention type | Biological, Drug |
| Interventions | PEG-interferon alfa-2a, gefitinib |
| Enrollment | 16 |
| Start date | Sep 1, 2006 |
| Primary completion | Jan 1, 2008 |
| First posted | Jan 18, 2007 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: